Ann: ANP to present at Neuromuscular Drug Development Summit USA, page-2

Antisense Therapeutics (“ANP” or the “Company”) is pleased to announce that Dr George Tachas, ANP’s Director of Drug Discovery and Patents, will be giving a poster presentation at the 2ndNeuromuscular Drug Development Summit (NMD) in Boston, MA, USA on 24 October 2019.

Results

The preliminary data review suggested a positive drug effect of ATL1102 at the dose tested both at immunomodulatory (i.e. effects on relevant immune cells) and disease progression (i.e. effects on muscle strength) levels. With respect to the safety related trial data, no Serious Adverse Events (SAE’s) had been reported to date. The Data Safety Monitoring Board had evaluated the safety data at that time and recommended continuation of the trial with no safety concerns. The number of immune T cells expressing CD49d, were trending downward during the 24 week treatment phase while returning to around starting levels post dosing. As an indicator of ATL1102’s suggestive effects on disease progression the patients pinch and grip strength as assessed by the Myo-Pinch and Myo-Grip device increased from baseline by a mean +0.1 kg 95% CI [-0.23, 0.34] and +0.3 kg 95% CI [-0.38, 1.08] respectively. This is compared to losses in muscle pinch and grip strength of -0.38kg 95%

CI [-0.53, -0.22] and -0.5 kg [-1.01, 0.002] respectively reported in a study in 9 non- ambulant DMD patients on corticosteroids assessed at 6 months4.

Conclusions

In an ongoing study of ATL1102 in patients with DMD treated for 24 weeks, no SAE’s have been reported while preliminary trial data from the first 6 patients having completed their dosing is suggestive of a drug effect of ATL1102 on the CD49d+ T cell numbers and the upper limb muscle grip and pinch strength.



More Good News is always welcome!!